AUTL · NASDAQ
Autolus Therapeutics plc
$1.42 +0.01 (+0.71%)
Company overview
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trial targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $378M
- Employees
- 647
- Headquarters
- London
- Website
- autolus.com
- CEO
- Christian Martin Itin
- Listed
- June 22, 2018
- P/E
- -1.30
- Dividend yield
- 0.00%
Company financials
- Revenue
- $92.6M
- Gross profit
- -$10.4M
- Operating income
- -$265M
- EBITDA
- -$248M
- Net income
- -$289M
- EPS
- -$1.09
- Total assets
- $527M
- Total debt
- $80M
- Gross margin
- -11.19%
- Net margin
- -311.95%
- Earnings yield
- -76.76%
Showing FY 2025
AUTL
1D
NASDAQ
O1.55H1.56L1.39C1.42-0.10 (-6.58%)Vol4.70M
News